Boehringer Ingelheim Pharmaceuticals recently began a clinical trial to assess the effect of Ofev (nintedanib) on specific blood biomarkers that may identify greater fibrosis and loss of lung function in patients with idiopathic pulmonary fibrosis (IPF). Biomarkers are measurable indicators of some biological state or condition that help predict disease…
Trial to Evaluate Ofev Impact on Predictive Biomarkers for IPF Progression Begins
The U.S. Department of Defense granted $11.5 million to researchers at National Jewish Health, one of the leading respiratory hospitals in the country, for two research projects investigating lung disease including pulmonary fibrosis in warfighters deployed to Southwest Asia.
MediciNova received a notice of allowance for a new patent covering MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of fibrosis,  broadly defined as wide-ranging fibrosis or fibrotic diseases, affecting different organs and due to different etiologies, including pulmonary fibrosis. Once issued by the U.S. Patent and…
High levels of  gremlin-1, a protein important in lung and other organ development, promoted a more aggressive fibrotic response in a mouse model of idiopathic pulmonary fibrosis (IPF) upon exposure to silica, suggesting  gremlin-1 as a potential target for IPF therapeutics. The study “Gremlin-1 Overexpression in Mouse Lung Reduces Silica-Induced Lymphocyte Recruitment –…
AdAlta has issued an initial public offering (IPO) on the Australian Stock Exchange to raise AU $10 million (US $7.5 million), to fund clinical studies for AD-114, the company’s leading compound under development for idiopathic pulmonary fibrosis (IPF) and other fibrotic disease. An (IPO) is the first sale of stock by…
Researchers in Japan identified several risk factors for an acute exacerbation, or sudden disease worsening, in people with idiopathic pulmonary fibrosis (IPF), including cardiovascular disease and older age, especially in men. The study, “Risk factors for an acute exacerbation of idiopathic pulmonary fibrosis,“ was published on July 11 in the journal…
A new review covering the benefits of exercise training in idiopathic pulmonary fibrosis (IPF) has been recently published in the journal Breathe.
A biochemical pathway in the lungs, in which an antioxidant called glutathione (GSH) binds to and changes the nature of specific proteins, may be involved in the development of pulmonary fibrosis, according to researchers at the University of Vermont. The study, “Attenuation of lung fibrosis in mice with a clinically relevant…
Windtree Therapeutics announced it has received $1 million as a third payment under a Phase 2 Small Business Innovation Research (SBIR) grant, worth in total about $3 million. The award is being used to advance preclinical testing of its aerosolized KL4 surfactant to ease radiation-induced lung injury, whose long-term effects can lead to…
Dr. Fernando Martinez, a clinical specialist in lung diseases such as idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD), is the newest member of the scientific and medical advisory board of ProterixBio, the company announced. His appointment as scientific and medical advisor reflects the company’s focus on solutions to improve care…
